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We present a case of fatal hemorrhagic pneumonia secondary to Stenotrophomonas maltophilia in a
patient with acute myeloid leukemia. S. maltophilia is commonly a non-virulent pathogen. However, in
the immunocompromised, it is generally associated with bacteremia after central venous catheter
placement or pneumonia. Hemorrhagic pneumonia is a rare presentation of this bacteria, with only 31
cases reported in the literature, and has 100% mortality within 72 hours. Rapid recognition and early
suspicion should be key in the treatment of these patients.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Case report
A 59 year old man with history of acute myeloid leukemia in
remission and undergoing chemotherapy treatment in preparation
for stem cell transplant, presented to the emergency department
with fever. At the time he was found to be febrile, tachypneic and
hypoxic on room air. Laboratory work up was signiﬁcant for neu-
tropenia which was present for at least 23 days, a normal coagu-
lation proﬁle and mild thrombocytopenia (56.000 Ƙ/mL). A chest-X
ray showed a left lung base inﬁltrate suggestive of pneumonia
(Fig. 1a). He was admitted to the hospital and started on antibiotics
for health care associated bacterial pneumonia and ﬂuconazole for
possible fungal infection. Within 36 hours of admission he was
transferred to the Intensive Care Unit (ICU) with frank hemoptysis,
respiratory failure and refractory shock. Chest X-ray at the time
showed progression of the pulmonary inﬁltrates on the left upper
and middle lobes (Fig. 1b). A bronchoscopy performed to further
asses the source of bleeding revealed no endobronchial lesions, but
there was evidence of profuse hemorrhage from the posterior basal
segment of the left lower lobe (Fig. 2). Bronchoscopic interventions
such as instillation of epinephrine, cold saline and thrombine, Division of Anesthesiology
son Cancer Center, 1515 Hol-
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Ltd. This is an open access article usolution, were unsuccessful to stop the bleeding. The patient’s
respiratory status continued to deteriorate requiring PEEP of 15 and
100% FiO2 and later onwas initiated on APRVmode, but still unable
to tolerate FiO2 less than 100%. ABGs at the time continued to show
severe hypoxemia and respiratory acidosis (7.27/42/63/89%).
Admission blood cultures and bronchial washing revealed gram-
negative rods that were later identiﬁed as Stenotrophomonas mal-
tophilia. Upon recognition of the bacteria trimethoprim/sulfa-
methoxazole (TMP-SMX) was initiated. Despite aggressive support,
the patient continued to deteriorate and died within 24 h of ICU
admission (Fig. 1c).2. Discussion
The differential diagnosis of pathogens causing pneumonia in
the immunocompromised host are extensive. The predominant
organisms in the non-neutropenic phase of patients with hema-
tological malignancies include Streptococcus pneumoniae, Haemo-
philus inﬂuenzae, and community-acquired respiratory viruses such
as inﬂuenza, parainﬂuenza, respiratory syncytial virus, and adeno-
virus [1]. Common gram negative organisms include Serratia,
Pseudomonas, Acinetobacter, Citrobacter and enterobacter(1). When
neutropenia has less than 1 week of onset common pathogens for
pneumonia are Pseudomonas aeruginosa, Enterobacteraceae,
S. pneumonia, Inﬂuenza virus and RSV infections. After the second
week of neutropenia organisms such as Serratia, Pseudomonas,
Acinetobacter, Citrobacter, Enterobacter and mold are more common
(1). In prolonged neutropenia the organisms are similar to those innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Progression of chest X-ray in a patient with S. maltophilia hemorrhagic pneumonia. a. Portable chest X-ray on admission. b. Post-intubation portable chest X-ray, 36 hours
after admission to the hospital c. Portable chest X-ray 72 hours after hospital admission.
Fig. 2. Evidence of active bleeding during bronchoscopy from posterior basal segment
of the left lower lobe.
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S. maltophilia is usually a non-virulent, gram-negative bacillus
found as an airway colonizer in the immunocompetent host [2e5].
Since the 1990s however, this bacteria has emerged as an important
nosocomial pathogen [2e5]. In immunocompromised patients,
S. maltophilia commonly causes pneumonia and bacteremiaassociated with central venous catheter infections [2,3,5]. Other
sites of infection include the eye, soft tissues, joints, meninges,
endocardium and urinary tract [4]. In immunocompromised pa-
tients, and speciﬁcally cancer patients, risk factors for infection
include neutropenia, prolonged ICU stay, prior use of broad spec-
trum antibiotics and mechanical ventilation [6]. If a patient has any
of these risk factors mortality ranges between 14 and 77%; more-
over, mortality is higher when bacteremia is secondary to central
venous catheter placement and when the patient has required
mechanical ventilation [3,4]. When S. maltophilia pneumonia de-
velops in a patient without risk factors, it is usually a mild lobar
pneumonia and can be treated as an outpatient [6,7]. On the con-
trary, in the presence of any risk factors, patients can develop a
disease severe enough to require ICU admission, and carries a
mortality as high as 50% [6,7].
Hemorrhagic pneumonia is a rare presentation of S. maltophilia.
To our knowledge, only 31 cases are reported in the literature and
they are all in patients with hematological malignancies [3,5]. The
exact mechanism by which S. maltophilia causes hemorrhage is
unknown. A study by Windhorst et al., suggests that StmPr1, a
protease of the subtilase family, is secreted by the bacteria leading
to tissue invasion, destruction and hemorrhage [8]. Hemorrhagic
pneumonia by S. maltophilia develops in patients who have recently
received chemotherapy or a hematopoietic stem cell transplant [5].
Eighty-four percent of these patients have bacteremia, and their
clinical presentation is severe with 100% mortality within 72 hours
of diagnosis [5,9]. Due to its severity and rapid progression, early
suspicion is important; however, efforts for surveillance and pro-
phylaxis are so far limited. In a systematic review of the literature
surveillance sputum cultures were positive in only 30% of patients
who developed hemorrhagic pneumonia [3]. Also, despite pro-
phylaxis with quinolones or co-trimoxazole, mortality was un-
changed for patients who developed hemorrhagic pneumonia [3,5].
While immunosuppression is a signiﬁcant risk factor for
S. maltophilia infection, it is important to recognize that other in-
fectious causes for hemoptysis such as aspergillomas and tuber-
culosis should be considered in this population [10].
S. maltophilia is resistant to third generation cephalosporins, b-
lactams, carbapenems and aminoglycosides, all of which are
commonly used as initial therapy for pneumonia in the immuno-
compromised [3e6]. While the mechanism of resistance is not
completely understood, it is believed that low membrane perme-
ability and chromosomally encoded efﬂux pumps cause resistance
to beta-lactamases, aminoglycosides and quinolones [4,6]. Another
limitation to adequate treatment of this pathogen is that in-vitro
results of susceptibility for S. maltophilia are not standardized; this
C. Gutierrez et al. / Respiratory Medicine Case Reports 19 (2016) 12e1414leads to discrepancy when reporting results and can impact treat-
ment efﬁcacy [4,6]. TMP-SMX is considered the drug of choice.
Dosing, while not clinically studied, should be similar as in pneu-
mocystis treatment [3e5]. Increasing resistance to TMP-SMX is
reported, and it is now debated whether synergistic double
coverage therapy should be recommended for initial treatment.
Combination therapy should include TMP-SMX and addition of
quinolones, colistin, ticarcillin-clavulanate, ceftazidime or aztreo-
nam [4e7]. When considering quinolones, moxiﬂoxacin has shown
to have better in-vitro activity against S. maltophilia when
compared to ciproﬂoxacin [11]. Data on the efﬁciency and clinical
response of combination therapy is scarce and no clinical studies
are available [4,6].
3. Conclusion
Commonly, invasive fungal pneumonia is suspected in immu-
nocompromised patients with hemorrhagic pneumonia; however,
S. maltophilia should be considered in the differential diagnosis in
patients with risk factors. Heightened clinical suspicion and early
treatment may lead to increased survival.
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